Medical therapy for benign prostatic hyperplasia: a review of the literature.
about
Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.Pharmacogenetics of human androgens and prostatic diseases.The shrinking case for saw palmettoTargeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway?Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia.Management of bladder, prostatic and pelvic floor disorders.5alpha-reductase inhibition for men with enlarged prostate.In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity.Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in ratsEffects of D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia) or the lipidosterolic extract of saw palmetto (Serenoa repens) on the sexual activity in male rats: A controlled, experimental study.Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Benign prostate hyperplasia and stem cells: a new therapeutic opportunity.Non-Hormonal treatment of BPH/BOOImpact of changing trends in medical therapy on surgery for benign prostatic hyperplasia over two decades.Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms.The impact of metabolic syndrome on the responsiveness to α1-blocker in men with BPH/LUTS.Drug or symptom-induced depression in men treated with alpha 1-blockers for benign prostatic hyperplasia? A nested case-control study.Use of alpha-blockers and the risk of hip/femur fractures.The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia.The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).Treatment of Benign Prostatic Hyperplasia by Ultrasound-Guided Botulinum Toxin Type A Injection.The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses.Effects of coconut oil on testosterone-induced prostatic hyperplasia in Sprague-Dawley rats
P2860
Q24795452-5D3DAE2E-5EFE-43DF-9451-235A12B41A0DQ33262634-7C702566-C68D-42A6-9032-57998E92B3EAQ34189642-720D495E-068D-41BF-8EAB-353F57DD157DQ34789608-A6324CE7-79DC-47C2-B9D3-8F91C581690DQ36206614-45AFF064-7F83-445A-A5C7-12A9E09C49BCQ36498032-42A433FA-709F-4192-BC49-F55C522C6AC9Q36511604-91B526C9-6BCF-41DA-8CEC-B9D81DFBDB53Q36892851-210B0FC0-56D0-48D2-BC5B-ABABC1ADD26FQ37663475-6EB556BC-22D3-4371-A72A-B42152E48740Q37663481-BF796716-2247-444A-9D8A-38518F8B3A74Q37672774-311CB710-7D59-4D64-A22F-5B44D18027ABQ37790387-7A33B418-1B1C-483D-853C-42C196DC862EQ38038271-9356A1D9-C8F6-4C7C-BA71-346C95DBDBBDQ38052058-B77C2470-D376-4A0A-BBC6-71F23AF12AEAQ38205423-688AFB48-283A-49A4-9C06-9C2238A70E05Q38465520-184AC6A7-053D-4C9F-BE73-ED5AAF5B48EAQ39387626-0083F72E-65D0-4777-9662-55BDA39645E4Q43574338-A1D89256-9DBE-4887-924A-F74B25110A5EQ43947333-D808A2ED-1750-4214-B0A9-0166F3C64F5CQ44671122-0096182F-B727-478D-865E-1528B36ED9B7Q45260612-792BA868-74FB-41E6-85E4-0A81BD79D598Q45713774-ED0A3F12-AA0A-48CF-855B-E38AB18D47FDQ46753219-842AE930-A448-4D5E-AF9C-83A17D2E9641Q47713020-89D66441-CC6E-4718-86CC-F1961DC9FC79Q47866814-371313EE-8C15-4E61-8595-CA7331598A1EQ53123387-0802F412-858C-4A5C-8D26-62CD23D5D3BCQ56906851-AA7D9DD8-7B52-4AA3-A2A4-8D4FD295B011
P2860
Medical therapy for benign prostatic hyperplasia: a review of the literature.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Medical therapy for benign prostatic hyperplasia: a review of the literature.
@ast
Medical therapy for benign prostatic hyperplasia: a review of the literature.
@en
type
label
Medical therapy for benign prostatic hyperplasia: a review of the literature.
@ast
Medical therapy for benign prostatic hyperplasia: a review of the literature.
@en
prefLabel
Medical therapy for benign prostatic hyperplasia: a review of the literature.
@ast
Medical therapy for benign prostatic hyperplasia: a review of the literature.
@en
P356
P1433
P1476
Medical therapy for benign prostatic hyperplasia: a review of the literature.
@en
P2093
G M Clifford
R D Farmer
P356
10.1159/000020246
P407
P577
2000-07-01T00:00:00Z